OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Trading Down 17.1 %

OPGN stock opened at $1.50 on Monday. The business’s fifty day moving average price is $1.82 and its two-hundred day moving average price is $2.42. OpGen has a fifty-two week low of $1.40 and a fifty-two week high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.